These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 25733532)

  • 21. Exploring the relationship between North Star Ambulatory Assessment and Health Utilities Index scores in Duchenne muscular dystrophy.
    Audhya I; Rogula B; Szabo SM; Feeny D; Bolatova T; Gooch K
    Health Qual Life Outcomes; 2023 Jul; 21(1):76. PubMed ID: 37468890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy.
    Ricotti V; Ridout DA; Scott E; Quinlivan R; Robb SA; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2013 Jun; 84(6):698-705. PubMed ID: 23250964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy.
    Mazzone ES; Pane M; Sormani MP; Scalise R; Berardinelli A; Messina S; Torrente Y; D'Amico A; Doglio L; Viggiano E; D'Ambrosio P; Cavallaro F; Frosini S; Bello L; Bonfiglio S; De Sanctis R; Rolle E; Bianco F; Magri F; Rossi F; Vasco G; Vita G; Motta MC; Donati MA; Sacchini M; Mongini T; Pini A; Battini R; Pegoraro E; Previtali S; Napolitano S; Bruno C; Politano L; Comi GP; Bertini E; Mercuri E
    PLoS One; 2013; 8(1):e52512. PubMed ID: 23326337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Expert recommendation: treatment of nonambulatory patients with Duchenne muscular dystrophy].
    Bernert G; Hahn A; Köhler C; Meyer S; Schara U; Schlachter K; Trollmann R; Walter MC
    Nervenarzt; 2021 Apr; 92(4):359-366. PubMed ID: 33215271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genotype-related respiratory progression in Duchenne muscular dystrophy-A multicenter international study.
    Trucco F; Ridout D; Domingos J; Maresh K; Chesshyre M; Munot P; Sarkozy A; Robb S; Quinlivan R; Riley M; Wallis C; Chan E; Abel F; De Lucia S; Hogrel JY; Niks EH; de Groot I; Servais L; Straub V; Ricotti V; Manzur A; Muntoni F;
    Muscle Nerve; 2022 Jan; 65(1):67-74. PubMed ID: 34606104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The natural history of the patients with Duchenne muscular dystrophy in Taiwan: A medical center experience.
    Liang WC; Wang CH; Chou PC; Chen WZ; Jong YJ
    Pediatr Neonatol; 2018 Apr; 59(2):176-183. PubMed ID: 28903883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and mutational characteristics of Duchenne muscular dystrophy patients based on a comprehensive database in South China.
    Wang DN; Wang ZQ; Yan L; He J; Lin MT; Chen WJ; Wang N
    Neuromuscul Disord; 2017 Aug; 27(8):715-722. PubMed ID: 28318817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.
    Shimizu-Motohashi Y; Murakami T; Kimura E; Komaki H; Watanabe N
    Orphanet J Rare Dis; 2018 Jun; 13(1):93. PubMed ID: 29907124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy.
    Bello L; Piva L; Barp A; Taglia A; Picillo E; Vasco G; Pane M; Previtali SC; Torrente Y; Gazzerro E; Motta MC; Grieco GS; Napolitano S; Magri F; D'Amico A; Astrea G; Messina S; Sframeli M; Vita GL; Boffi P; Mongini T; Ferlini A; Gualandi F; Soraru' G; Ermani M; Vita G; Battini R; Bertini E; Comi GP; Berardinelli A; Minetti C; Bruno C; Mercuri E; Politano L; Angelini C; Hoffman EP; Pegoraro E
    Neurology; 2012 Jul; 79(2):159-62. PubMed ID: 22744661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic modifiers of respiratory function in Duchenne muscular dystrophy.
    Bello L; D'Angelo G; Villa M; Fusto A; Vianello S; Merlo B; Sabbatini D; Barp A; Gandossini S; Magri F; Comi GP; Pedemonte M; Tacchetti P; Lanzillotta V; Trucco F; D'Amico A; Bertini E; Astrea G; Politano L; Masson R; Baranello G; Albamonte E; De Mattia E; Rao F; Sansone VA; Previtali S; Messina S; Vita GL; Berardinelli A; Mongini T; Pini A; Pane M; Mercuri E; Vianello A; Bruno C; Hoffman EP; Morgenroth L; Gordish-Dressman H; McDonald CM; ; Pegoraro E
    Ann Clin Transl Neurol; 2020 May; 7(5):786-798. PubMed ID: 32343055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.
    Bello L; Gordish-Dressman H; Morgenroth LP; Henricson EK; Duong T; Hoffman EP; Cnaan A; McDonald CM;
    Neurology; 2015 Sep; 85(12):1048-55. PubMed ID: 26311750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular and Clinical Characteristics of a National Cohort of Paediatric Duchenne Muscular Dystrophy Patients in Norway.
    Annexstad EJ; Fagerheim T; Holm I; Rasmussen M
    J Neuromuscul Dis; 2019; 6(3):349-359. PubMed ID: 31381525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures.
    Henricson EK; Abresch RT; Cnaan A; Hu F; Duong T; Arrieta A; Han J; Escolar DM; Florence JM; Clemens PR; Hoffman EP; McDonald CM;
    Muscle Nerve; 2013 Jul; 48(1):55-67. PubMed ID: 23649481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
    Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.
    Mercuri E; Signorovitch JE; Swallow E; Song J; Ward SJ; ;
    Neuromuscul Disord; 2016 Sep; 26(9):576-83. PubMed ID: 27423700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up.
    Coratti G; Pane M; Brogna C; Ricotti V; Messina S; D'Amico A; Bruno C; Vita G; Berardinelli A; Mazzone E; Magri F; Ricci F; Mongini T; Battini R; Bello L; Pegoraro E; Baranello G; Previtali SC; Politano L; Comi GP; Sansone VA; Donati A; Hogrel JY; Straub V; De Lucia S; Niks E; Servais L; De Groot I; Chesshyre M; Bertini E; Goemans N; Muntoni F; Mercuri E;
    PLoS One; 2021; 16(6):e0253882. PubMed ID: 34170974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of motor proficiency and functional ambulation in Duchenne muscular dystrophy with healthy peers.
    Yildiz S; Sahin S; Bulut N; Tunca Yilmaz O; Karaduman AA; Akel BS
    Somatosens Mot Res; 2020 Dec; 37(4):252-256. PubMed ID: 32583706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy.
    Ayyar Gupta V; Pitchforth JM; Domingos J; Ridout D; Iodice M; Rye C; Chesshyre M; Wolfe A; Selby V; Mayhew A; Mazzone ES; Ricotti V; Hogrel JY; Niks EH; de Groot I; Servais L; Straub V; Mercuri E; Manzur AY; Muntoni F;
    PLoS One; 2023; 18(4):e0283669. PubMed ID: 37099511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.